Michael DePasquale
Analyst
Thanks, Bill, and thanks to everyone for joining us today. After my remarks, Ceci will review the financials, and we'll open up the call to investor questions. Our Q1 '26 results and Q2 '26 outlook reflect the benefit of our team's hard work, particularly over the last year, we're also seeing expanded appreciation for the unparalleled value that our biometric identity and access management solutions provide in securing mission-critical applications and data. Borrowing the old phrase, BIO-key has built a powerful suite of biometric solutions with the belief that customers will come. That strategy is really starting to play out for us in a meaningful way, and I will discuss that. Our Q1 '26 revenues reflect both new customer wins and growing long-term customer deployments in defense and financial services. Last year, we launched our defense and intelligence cybersecurity initiative targeted primarily in foreign markets for more secure identity and access management solutions. Our customer base now includes several of the world's most prominent and significant defense organizations, and our success in meeting their strategic needs is proving very valuable in supporting new opportunities. But it's not just government, defense and highly regulated industries. We're also seeing traction with enterprise customers, particularly in EMEA and the EMEA markets. Our progress in these regions is supported by an expanding base of strong regional distribution partners as well as foreign regulatory frameworks that are favorable to our strong biometric options. Outside of EMEA, we have also added new partners in India and Vietnam, where we are seeing solid opportunities in future periods as these partners ramp up their marketing and sales efforts. To better reach public sector opportunities in the U.S., which often require working with a preapproved vendor, we recently partnered with DLT Solutions, a division of TD Synnex, the world's largest IT distributor and solutions aggregator. TD Synnex employs 23,000 people globally and offers a massive portfolio of IT hardware, software, cybersecurity and cloud services to over 150,000 customers in more than 100 countries, while DLT is their kind of public sector arm domestically. We're integrating our PortalGuard IAM and Passkey:YOU biometric solutions into DLT's platform of offerings. The partnership provides a streamlined procurement path, enabling their extensive base of public sector customers to easily purchase and deploy our solutions, many of which face mandates to adopt Zero Trust digital infrastructure and implement multifactor authentication. With our solutions, customers can easily meet these requirements and anchor digital access to a person, rather than to just a device. We're working closely with the DLT team to help them educate public sector customers on the solutions and compelling ROI that BIO-key can provide. On our year-end call, I reviewed several factors that are shaping the market for our solutions today. So I'll just provide a brief overview of those. First, the continued expansion of digital services and mobile use cases that require secure authentication is widening our market opportunity. Second, we believe demand for the secure digital access BIO-key uniquely provides will continue to expand as organizations confront a more sophisticated and persistent cybersecurity threat landscape. Third, we expect passwordless authentication to continue to gain traction and become the standard this year and beyond, as enterprises look to reduce risk from phishing, credential reuse and misuse as well as account takeover attacks. BIO-key enables unique and highly secure passwordless solutions. Fourth, biometric authentication should see growing adoption in the highest value use cases as we've seen in military, defense, financial services, health care and other highly regulated industries where security and trust are most critical. Fifth, the rise of AI-driven threats really escalates the need for more resilient identity strategies that surpass vulnerable, yet widely deployed authentication methods like phones. And finally, the market is moving towards more unified access platforms that unite workforce, partner and privileged access under a single flexible foundation. These trends play directly into BIO-key's strengths, and we are starting to see them in our financial results. Today, our business is predominantly a subscription-based business with recurring revenues. Approximately 50% of our new business comes through our partnership model domestically. And as I've mentioned a number of times before, 100% of our business is sold through channel partners internationally, providing a very, very efficient and more importantly, a scalable model. I also want to mention that we launched a new website in mid-April, that is designed to better support our partners and customers in understanding how BIO-key can meet their needs. We believe it's an important step to support our growth goals. I want to thank our team who put a lot of hard work and effort into this launch, and I encourage investors to review it at www.bio-key.com. And as always, we welcome any feedback that you can provide. From a financial standpoint, BIO-key is in a solid position to continue to fund our growth. We ended Q1 with a book value of $7.6 million, or approximately $7 a share, including over $2 million, or $2.07 per share in cash, and we expect this position to continue to hold or improve as we approach the second quarter -- the end of the second quarter. As we mentioned a few days ago, our shares were recently suspended from NASDAQ. Today, we are actively working to return our shares to the NASDAQ capital market and have secured an appeals hearing, which will be held on June 16, which is next month, about 4 weeks from tomorrow. In the interim, our shares continue to trade on the OTC markets under the symbol BKYI. Although we cannot be certain of the success or timing of the panel's decision, our advisers believe there is reason for optimism regarding a return to NASDAQ trading by the summer. In summary, our business is off to a very strong start, and we are confident in our first half outlook and very optimistic regarding the balance of the year and beyond. After years of hard work, we believe BIO-key has never been better positioned for growth and improved financial performance, and we will continue to update you, all of our shareholders, on our business and listing process as we proceed forward. With that, I'll turn the call over to Ceci to review the Q1 financial results.